NEWS
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory ADCs (iADC) that combine immune activation with cytotoxic payloads.
Key highlights include:
STRO-004, a tissue factor-targeting ADC, demonstrated greater anti-tumor activity and lower toxicities in preclinical models
Plans to file an IND for STRO-004 in the second half of 2025
Dual-payload ADCs (ADC2) show increased anti-tumor activity in preclinical models
iADCs provide a novel mechanism of action, bridging innate and adaptive immunity
Sutro plans to deliver three INDs over the next three years
Key highlights include:
STRO-004, a tissue factor-targeting ADC, demonstrated greater anti-tumor activity and lower toxicities in preclinical models
Plans to file an IND for STRO-004 in the second half of 2025
Dual-payload ADCs (ADC2) show increased anti-tumor activity in preclinical models
iADCs provide a novel mechanism of action, bridging innate and adaptive immunity
Sutro plans to deliver three INDs over the next three years
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2465Followers
107Following
26KVisitors
Follow